Monoamine abnormalities in the SAPAP3 knockout model of obsessive-compulsive disorder-related behaviour

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 373, Issue 1742, 2018, Pages

  Wood, Jesse ^a,b   LaPalombara, Zoe ^a,b   Ahmari, Susanne E ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Basal ganglia; HPLC; Monoamines; Obsessive compulsive disorder; Orbitofrontal cortex; SAPAP3 KO

Indexed keywords

ABNORMALITY; BEHAVIOR; EXPERIMENTAL STUDY; GENE; GROOMING; METABOLITE; NUMERICAL MODEL; PHYSIOLOGY;

ANIMALIA; MUS;

BIOGENIC AMINE; SEROTONIN;

ANIMAL; DISEASE MODEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; VENTRAL STRIATUM;

ANIMALS; BIOGENIC MONOAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; OBSESSIVE-COMPULSIVE DISORDER; PREFRONTAL CORTEX; SEROTONIN; VENTRAL STRIATUM;

EID: 85040917796     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2017.0023     Document Type: Article

References (112)

1. Pauls DL, Abramovitch A, Rauch SL, Geller DA. 2014 Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat. Rev. Neurosci. 15, 410–424. (doi:10.1038/nrn3746)
2. Wood J, Ahmari SE. 2015 A Framework for understanding the emerging role of corticolimbic-ventral striatal networks in OCD-associated repetitive behaviors. Front. Syst. Neurosci. 9, 171. (doi:10.3389/fnsys.2015.00171)
3. Rasmussen SA, Eisen JL. 1990 Epidemiology of obsessive compulsive disorder. J. Clin. Psychiatry 51 Suppl:10–3; discussion 4, 10–14.
4. Ahmari SE, Dougherty DD. 2015 Dissecting Ocd circuits: from animal models to targeted treatments. Depress. Anxiety 32, 550–562. (doi:10.1002/da. 22367)
5. Karno M, Golding JM, Sorenson SB, Burnam MA. 1988 The epidemiology of obsessive-compulsive disorder in five US communities. Arch. Gen. Psychiatry 45, 1094–1099. (doi:10.1001/archpsyc. 1988.01800360042006)
6. Torres AR et al. 2006 Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British national psychiatric morbidity survey of 2000. Am. J. Psychiatry 163, 1978–1985. (doi:10.1176/ajp.2006.163.11.1978)
7. Milad MR, Rauch SL. 2012 Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn. Sci. 16, 43–51. (doi:10. 1016/j.tics.2011.11.003)
8. Graybiel AM, Rauch SL. 2000 Toward a neurobiology of obsessive-compulsive disorder. Neuron 28, 343–347. (doi:10.1016/S0896-6273(00)00113-6)
9. Denys D et al. 2013 Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 23, 1423– 1431. (doi:10.1016/j.euroneuro.2013.05.012)
10. Denys D, Zohar J, Westenberg HG. 2004 The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J. Clin. Psychiatry 65(Suppl. 14), 11–17.
11. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg H. 2006 Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur. Neuropsychopharmacol. 16, 446–450. (doi:10.1016/j.euroneuro.2005.12.001)
12. Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HG. 2004 Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol. Psychiatry 55, 1041–1045. (doi:10.1016/j. biopsych.2004.01.023)
13. Klanker M, Feenstra M, Denys D. 2013 Dopaminergic control of cognitive flexibility in humans and animals. Front. Neurosci. 7, 201. (doi:10.3389/fnins. 2013.00201)
14. Figee M et al. 2014 Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder. Biol. Psychiatry 75, 647–652. (doi:10. 1016/j.biopsych.2013.06.021)
15. Figee M, Pattij T, Willuhn I, Luigjes J, van den Brink W, Goudriaan A, Potenza MN, Robbins TW, Denys D. 2016 Compulsivity in obsessive-compulsive disorder and addictions. Eur. Neuropsychopharmacol. 26, 856–868. (doi:10.1016/j.euroneuro.2015.12.003)
16. Figee M, Vink M, de Geus F, Vulink N, Veltman DJ, Westenberg H, Denys D. 2011 Dysfunctional reward circuitry in obsessive-compulsive disorder. Biol. Psychiatry 69, 867–874. (doi:10.1016/j.biopsych. 2010.12.003)
17. Insel TR. 1990 New pharmacologic approaches to obsessive compulsive disorder. J. Clin. Psychiatry 51 (Suppl. 47–51); discussion 6–8, 47–58.
18. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. 1985 Obsessive-compulsive disorder and serotonin: is there a connection? Biol. Psychiatry 20, 1174–1188. (doi:10.1016/0006-3223(85)90176-3)
19. Insel TR, Winslow JT. 1992 Neurobiology of obsessive compulsive disorder. Psychiatr. Clin. North Am. 15, 813–824. (doi:10.1097/00004850-199206001-00008)
20. Koran LM, Pallanti S, Quercioli L. 2001 Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 11, 169–172. (doi:10.1016/S0924-977X(01)00082-7)
21. Khanna S, John JP, Reddy LP. 2001 Neuroendocrine and behavioral responses to mCPP in obsessive-compulsive disorder. Psychoneuroendocrinology 26, 209–223. (doi:10.1016/S0306-4530(00)00048-2)
22. Murphy DL, Moya PR, Fox MA, Rubenstein LM, Wendland JR, Timpano KR. 2013 Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Phil. Trans. R. Soc. B 368, 20120435. (doi:10.1098/rstb.2012.0435)
23. Taylor S. 2013 Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies. Mol. Psychiatry 18, 799–805. (doi:10.1038/mp.2012.76)
24. Cengiz M, Okutan SN, Bayoglu B, Sakalli Kani A, Bayar R, Kocabasoglu N. 2015 Genetic polymorphism of the serotonin transporter gene, SLC6A4 rs16965628, is associated with obsessive compulsive disorder. Genet. Test. Mol. Biomarkers 19, 228–234. (doi:10.1089/gtmb.2014.0319)
25. Walitza S, Marinova Z, Grunblatt E, Lazic SE, Remschmidt H, Vloet TD, Wendland JR. 2014 Trio study and meta-analysis support the association of genetic variation at the serotonin transporter with early-onset obsessive-compulsive disorder. Neurosci. Lett. 580, 100–103. (doi:10.1016/j.neulet.2014. 07.038)
26. Tukel R, Alkas E, Gurvit H, Aslantas Ertekin B, Ertekin E, Baran B, Kalem SA, Direskeneli GS. 2016 Serotonin transporter promoter polymorphism is associated with executive function impairments in patients with obsessive compulsive disorder. Clin. Neuropsychol. 30, 536–546. (doi:10.1080/13854046.2016.1162329)
27. Honda S et al. 2017 A pilot study exploring the association of morphological changes with 5-HTTLPR polymorphism in OCD patients. Ann. Gen. Psychiatry 16, 2. (doi:10.1186/s12991-017-0126-6)
28. Goddard AW, Shekhar A, Whiteman AF, McDougle CJ. 2008 Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov. Today 13, 325–332. (doi:10.1016/j.drudis. 2007.12.009)
29. Baumgarten HG, Grozdanovic Z. 1998 Role of serotonin in obsessive-compulsive disorder. Br. J. Psychiatry Suppl. 35, 13–20.
30. Sampaio T, Lima C, Corregiari F, Bernik M. 2016 The putative catalytic role of higher serotonin bioavailability in the clinical response to exposure and response prevention in obsessive-compulsive disorder. Rev. Bras. Psiquiatr. 38, 287–293. (doi:10. 1590/1516-4446-2015-1721)
31. Koo MS, Kim EJ, Roh D, Kim CH. 2010 Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. Expert Rev. Neurother. 10, 275–290. (doi:10.1586/ern.09.148)
32. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. 2006 A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol. Psychiatry 11, 622–632. (doi:10.1038/sj.mp. 4001823)
33. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. 2000 A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry 57, 794–801. (doi:10.1001/archpsyc.57.8.794)
34. Denys D, de Geus F, van Megen HJ, Westenberg HG. 2004 A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry 65, 1040–1048. (doi:10.4088/JCP.v65n0803)
35. Hesse S, Muller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K. 2005 Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. 140, 63–72. (doi:10.1016/j.pscychresns.2005.07.002)
36. Nikolaus S, Antke C, Beu M, Muller HW. 2010 Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders–results from in vivo imaging studies. Rev. Neurosci. 21, 119–139. (doi:10.1515/REVNEURO.2010.21.2.119)
37. Kim E, Naisbitt S, Hsueh YP, Rao A, Rothschild A, Craig AM, Sheng M. 1997 GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules. J. Cell Biol. 136, 669–678. (doi:10.1083/jcb.136.3.669)
38. Takeuchi M, Hata Y, Hirao K, Toyoda A, Irie M, Takai Y. 1997 SAPAPs. A family of PSD-95/SAP90-associated proteins localized at postsynaptic density. J. Biol. Chem. 272, 11 943–11 951. (doi:10.1074/jbc.272.18.11943)
39. Scannevin RH, Huganir RL. 2000 Postsynaptic organization and regulation of excitatory synapses. Nat. Rev. Neurosci. 1, 133–141. (doi:10.1038/35039075)
40. Kim E, Sheng M. 2004 PDZ domain proteins of synapses. Nat. Rev. Neurosci. 5, 771–781. (doi:10. 1038/nrn1517)
41. Zuchner S et al. 2009 Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol. Psychiatry 14, 6–9. (doi:10.1038/mp.2008.83)
42. Bienvenu OJ et al. 2009 Sapap3 and pathological grooming in humans: results from the OCD collaborative genetics study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B, 710–720. (doi:10. 1002/ajmg.b.30897)
43. Welch JM et al. 2007 Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448, 894–900. (doi:10.1038/nature06104)
44. Burguiere E, Monteiro P, Feng G, Graybiel AM. 2013 Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. Science 340, 1243–1246. (doi:10.1126/science. 1232380)
45. Wan Y, Ade KK, Caffall Z, Ilcim Ozlu M, Eroglu C, Feng G, Calakos N. 2014 Circuit-selective striatal synaptic dysfunction in the Sapap3 knockout mouse model of obsessive-compulsive disorder. Biol. Psychiatry 75, 623–630. (doi:10.1016/j.biopsych. 2013.01.008)
46. Ahmari SE, Spellman T, Douglass NL, Kheirbek MA, Simpson HB, Deisseroth K, Gordon JA, Hen R. 2013 Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science 340, 1234–1239. (doi:10.1126/science.1234733)
47. Burguiere E, Monteiro P, Mallet L, Feng G, Graybiel AM. 2015 Striatal circuits, habits, and implications for obsessive-compulsive disorder. Curr. Opin Neurobiol. 30, 59–65. (doi:10.1016/j.conb.2014. 08.008)
48. Franklin KBJ, Paxinos G. 2013 Paxinos and franklin’s The mouse brain in stereotaxic coordinates. 4th edn. Amsterdam, Netherlands: Academic Press, an imprint of Elsevier. 1 volume (unpaged) p.
49. Aghajanian GK, Rosecrans JA, Sheard MH. 1967 Serotonin: release in the forebrain by stimulation of midbrain raphe. Science 156, 402–403. (doi:10. 1126/science.156.3773.402)
50. Roth RH, Murrin LC, Walters JR. 1976 Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid. Eur. J. Pharmacol. 36, 163–171. (doi:10.1016/0014-2999(76)90268-5)
51. Sharp T, Zetterstrom T, Ungerstedt U. 1986 An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis. J. Neurochem. 47, 113–122. (doi:10.1111/j.1471-4159.1986.tb02838.x)
52. Remijnse PL, Nielen MM, van Balkom AJ, Cath DC, van Oppen P, Uylings HB, Veltman DJ. 2006 Reduced orbitofrontal-striatal activity on a reversal learning task in obsessive-compulsive disorder. Arch. Gen. Psychiatry 63, 1225–1236. (doi:10.1001/archpsyc.63.11.1225)
53. Chamberlain SR et al. 2008 Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 321, 421–422. (doi:10.1126/science.1154433)
54. Saxena S, Brody AL, Schwartz JM, Baxter LR. 1998 Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br. J. Psychiatry Suppl. 1998, 26–37.
55. Albelda N, Joel D. 2012 Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates. Neurosci. Biobehav. Rev. 36, 47–63. (doi:10.1016/j. neubiorev.2011.04.006)
56. Mahgoub M, Adachi M, Suzuki K, Liu X, Kavalali ET, Chahrour MH, Monteggia LM. 2016 MeCP2 and histone deacetylases 1 and 2 in dorsal striatum collectively suppress repetitive behaviors. Nat. Neurosci. 19, 1506–1512. (doi:10.1038/nn.4395)
57. Welch JM, Wang D, Feng G. 2004 Differential mRNA expression and protein localization of the SAP90/ PSD-95-associated proteins (SAPAPs) in the nervous system of the mouse. J. Comp. Neurol. 472, 24–39. (doi:10.1002/cne.20060)
58. Sesack SR, Grace AA. 2010 Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 35, 27–47. (doi:10. 1038/npp.2009.93)
59. Crittenden JR, Graybiel AM. 2011 Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front. Neuroanat. 5, 59. (doi:10.3389/fnana.2011.00059)
60. Albin RL, Young AB, Penney JB. 1989 The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366–375. (doi:10.1016/0166-2236(89)90074-X)
61. Graybiel AM. 2000 The basal ganglia. Curr. Biol. 10, R509–R511. (doi:10.1016/S0960-9822(00)00593-5)
62. Soiza-Reilly M, Commons KG. 2011 Glutamatergic drive of the dorsal raphe nucleus. J. Chem. Neuroanat. 41, 247–255. (doi:10.1016/j.jchemneu. 2011.04.004)
63. Commons KG, Beck SG, Bey VW. 2005 Two populations of glutamatergic axons in the rat dorsal raphe nucleus defined by the vesicular glutamate transporters 1 and 2. Eur. J. Neurosci. 21, 1577–1586. (doi:10.1111/j.1460-9568.2005. 03991.x)
64. McDougle CJ, Goodman WK, Leckman JF, Price LH. 1993 The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr. Clin. North Am. 16, 749–766.
65. Zitterl W et al. 2008 Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology 33, 3126–3134. (doi:10. 1038/npp.2008.35)
66. Zitterl W et al. 2009 Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers. Biol. Psychiatry 66, 1115–1122. (doi:10.1016/j.biopsych.2009.07.009)
67. Hesse S et al. 2011 The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 14, 606–617. (doi:10.1017/S1461145710001604)
68. Reimold M et al. 2007 Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study. J. Neural Transm. 114, 1603–1609. (doi:10.1007/s00702-007-0785-6)
69. Kim E, Howes OD, Park JW, Kim SN, Shin SA, Kim BH, Turkheimer FE, Lee Y-S, Kwon JS. 2016 Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study. Psychol. Med. 46, 357–366. (doi:10.1017/S0033291715001865)
70. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. 1987 Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch. Gen. Psychiatry 44, 946–951. (doi:10.1001/archpsyc.1987. 01800230026006)
71. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL. 1988 Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch. Gen. Psychiatry 45, 167–172. (doi:10.1001/archpsyc.1988.01800260081011)
72. Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjoqvist F, Traskman L. 1980 Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch. Gen. Psychiatry 37, 1289–1294. (doi:10.1001/archpsyc.1980. 01780240087010)
73. Flament MF, Rapoport JL, Murphy DL, Berg CJ, Lake CR. 1987 Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch. Gen. Psychiatry 44, 219–225. (doi:10.1001/archpsyc.1987.01800150025004)
74. Molloy AG, Waddington JL. 1984 Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390. Psychopharmacology 82, 409–410. (doi:10.1007/BF00427697)
75. Starr BS, Starr MS. 1986 Grooming in the mouse is stimulated by the dopamine D1 agonist SKF 38393 and by low doses of the D1 antagonist SCH 23390, but is inhibited by dopamine D2 agonists, D2 antagonists and high doses of SCH 23390. Pharmacol. Biochem. Behav. 24, 837–839. (doi:10. 1016/0091-3057(86)90421-1)
76. White FJ, Bednarz LM, Wachtel SR, Hjorth S, Brooderson RJ. 1988 Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors? Pharmacol. Biochem. Behav. 30, 189–193. (doi:10.1016/0091-3057(88)90442-X)
77. Berridge KC, Aldridge JW, Houchard KR, Zhuang X. 2005 Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette’s. BMC Biol. 3, 4. (doi:10.1186/1741-7007-3-4)
78. Einat H, Szechtman H. 1995 Perseveration without hyperlocomotion in a spontaneous alternation task in rats sensitized to the dopamine agonist quinpirole. Physiol. Behav. 57, 55–59. (doi:10. 1016/0031-9384(94)00209-N)
79. Mundt A et al. 2009 High-frequency stimulation of the nucleus accumbens core and shell reduces quinpirole-induced compulsive checking in rats. Eur. J. Neurosci. 29, 2401–2412. (doi:10.1111/j. 1460-9568.2009.06777.x)
80. Rudebeck PH, Murray EA. 2011 Balkanizing the primate orbitofrontal cortex: distinct subregions for comparing and contrasting values. Ann. N. Y. Acad. Sci. 1239, 1–13. (doi:10.1111/j.1749-6632.2011. 06267.x)
81. Noonan MP, Kolling N, Walton ME, Rushworth MF. 2012 Re-evaluating the role of the orbitofrontal cortex in reward and reinforcement. Eur. J. Neurosci. 35, 997–1010. (doi:10.1111/j.1460-9568.2012. 08023.x)
82. Schoenbaum G, Roesch MR, Stalnaker TA, Takahashi YK. 2009 A new perspective on the role of the orbitofrontal cortex in adaptive behaviour. Nat. Rev. Neurosci. 10, 885–892.
83. Schoenbaum G, Saddoris MP, Stalnaker TA. 2007 Reconciling the roles of orbitofrontal cortex in reversal learning and the encoding of outcome expectancies. Ann. N. Y. Acad. Sci. 1121, 320–335. (doi:10.1196/annals.1401.001)
84. Rolls E, Critchley H, Mason R, Wakeman E. 1996 Orbitofrontal cortex neurons: role in olfactory and visual association learning. J. Neurophysiol. 75, 1970–1981.
85. Rolls ET. 2000 The orbitofrontal cortex and reward. Cereb. Cortex 10, 284–294. (doi:10.1093/cercor/10.3.284)
86. Schultz W. 1998 Predictive reward signal of dopamine neurons. J. Neurophysiol. 80, 1–27.
87. Takahashi YK, Roesch MR, Stalnaker TA, Haney RZ, Calu DJ, Taylor AR, Burke KA, Schoenbaum G. 2009 The orbitofrontal cortex and ventral tegmental area are necessary for learning from unexpected outcomes. Neuron 62, 269–280. (doi:10.1016/j.neuron.2009.03.005)
88. Chamberlain SR, Fineberg NA, Blackwell AD, Robbins TW, Sahakian BJ. 2006 Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am. J. Psychiatry 163, 1282–1284. (doi:10.1176/ajp.2006.163.7.1282)
89. Montague PR, Dayan P, Sejnowski TJ. 1996 A framework for mesencephalic dopamine systems based on predictive Hebbian learning. J. Neurosci. 16, 1936–1947.
90. Glimcher PW. 2011 Understanding dopamine and reinforcement learning: the dopamine reward prediction error hypothesis. Proc. Natl. Acad. Sci. USA 108(Suppl. 3), 15 647–15 654. (doi:10.1073/pnas.1014269108)
91. Houk JC, Adams JL, Barto AG. 1995 A model of how the basal ganglia generate and use neural signals that predict reinforcement. Cambridge, MA: The MIT Press.
92. Joel D, Niv Y, Ruppin E. 2002 Actor-critic models of the basal ganglia: new anatomical and computational perspectives. Neural Netw. 15, 535–547. (doi:10.1016/S0893-6080(02)00047-3)
93. Bjorklund A, Dunnett SB. 2007 Dopamine neuron systems in the brain: an update. Trends Neurosci. 30, 194–202. (doi:10.1016/j.tins.2007.03.006)
94. Tecuapetla F, Jin X, Lima SQ, Costa RM. 2016 Complementary contributions of striatal projection pathways to action initiation and execution. Cell 166, 703–715. (doi:10.1016/j.cell.2016.06.032)
95. DeLong MR. 1990 Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281–285. (doi:10.1016/0166-2236(90)90110-V)
96. Kravitz AV, Freeze BS, Parker PR, Kay K, Thwin MT, Deisseroth K, Kreitzer AC. 2010 Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 466, 622–626. (doi:10.1038/nature09159)
97. Hong W, Kim DW, Anderson DJ. 2014 Antagonistic control of social versus repetitive self-grooming behaviors by separable amygdala neuronal subsets. Cell 158, 1348–1361. (doi:10.1016/j.cell. 2014.07.049)
98. Sorokin JM, Davidson TJ, Frechette E, Abramian AM, Deisseroth K, Huguenard JR, Paz JT. 2017 Bidirectional control of generalized epilepsy networks via rapid real-time switching of firing mode. Neuron 93, 194–210. (doi:10.1016/j.neuron. 2016.11.026)
99. O’Connor DH, Hires SA, Guo ZV, Li N, Yu J, Sun QQ, Huber D, Svoboda K. 2013 Neural coding during active somatosensation revealed using illusory touch. Nat. Neurosci. 16, 958–965. (doi:10.1038/nn.3419)
100. Sohal VS, Zhang F, Yizhar O, Deisseroth K. 2009 Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459, 698–702. (doi:10.1038/nature07991)
101. Krook-Magnuson E, Armstrong C, Bui A, Lew S, Oijala M, Soltesz I. 2015 In vivo evaluation of the dentate gate theory in epilepsy. J. Physiol. 593, 2379–2388. (doi:10.1113/JP270056)
102. Krook-Magnuson E, Szabo GG, Armstrong C, Oijala M, Soltesz I. 2014 Cerebellar directed optogenetic intervention inhibits spontaneous hippocampal seizures in a mouse model of temporal lobe epilepsy. eNeuro 1. (doi:10.1523/ENEURO.0005-14.2014)
103. Siegle JH, Wilson MA. 2014 Enhancement of encoding and retrieval functions through theta phase-specific manipulation of hippocampus. eLife 3, e03061. (doi:10.7554/eLife.03061)
104. Grosenick L, Marshel JH, Deisseroth K. 2015 Closed-loop and activity-guided optogenetic control. Neuron 86, 106–139. (doi:10.1016/j.neuron.2015. 03.034)
105. Paz JT, Davidson TJ, Frechette ES, Delord B, Parada I, Peng K, Deisseroth K, Huguenard JR. 2013 Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury. Nat. Neurosci. 16, 64–70. (doi:10.1038/nn.3269)
106. Stark E, Roux L, Eichler R, Senzai Y, Royer S, Buzsaki G. 2014 Pyramidal cell-interneuron interactions underlie hippocampal ripple oscillations. Neuron 83, 467–480. (doi:10.1016/j.neuron.2014.06.023)
107. Berndt A, Yizhar O, Gunaydin LA, Hegemann P, Deisseroth K. 2009 Bi-stable neural state switches. Nat. Neurosci. 12, 229–234. (doi:10.1038/nn.2247)
108. Liu Z, Wang Y, Cai L, Li Y, Chen B, Dong Y, Huang YH. 2016 Prefrontal cortex to accumbens projections in sleep regulation of reward. J. Neurosci. 36, 7897–7910. (doi:10.1523/JNEUROSCI.0347-16.2016)
109. Rogerson T, Jayaprakash B, Cai DJ, Sano Y, Lee YS, Zhou Y, Bekal P, Deisseroth K, Silva AJ. 2016 Molecular and cellular mechanisms for trapping and activating emotional memories. PLoS ONE 11, e0161655. (doi:10.1371/journal.pone.0161655)
110. Witten IB et al. 2011 Recombinase-driver rat lines: tools, techniques, and optogenetic application to dopamine-mediated reinforcement. Neuron 72, 721–733. (doi:10.1016/j.neuron.2011.10.028)
111. Yamamoto K et al. 2015 Chronic optogenetic activation augments abeta pathology in a mouse model of Alzheimer disease. Cell Rep. 11, 859–865. (doi:10.1016/j.celrep.2015.04.017)
112. Kim CK et al. 2016 Simultaneous fast measurement of circuit dynamics at multiple sites across the mammalian brain. Nat. Methods 13, 325–328. (doi:10.1038/nmeth.3770)